Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Attention Deficit Hyperactivity Disorder
U.S. Patent office sends allowance for attention deficit, hyperactivity drug
August 15th, 2005
Spectrum Pharmaceuticals, Inc. (SPPI) announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives." This patent, when issued, will protect SPI-339 for use in the treatment of attention deficit/hyperactivity disorders (ADHD) and other neurological disorders and will not expire until 2021. SPI-339 is an orally available small molecule drug that has potential applications for the treatment of attention disorders, memory acquisition and other cognitive...
Source: Pharma Business Week (2005-08-15)
|
